XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenue $ 0 $ 0 $ 70 $ 0
Operating Expenses:        
Research and development 1,959 2,542 6,815 8,384
General and administrative 2,455 2,794 8,385 9,076
Total operating expenses 4,414 5,336 15,200 17,460
Operating loss (4,414) (5,336) (15,130) (17,460)
Other income (expense):        
Investment income, net 183 451 665 1,533
Other expense, net (18) (45) (129) (246)
Total other income 165 406 536 1,287
Net loss before benefit from income taxes and noncontrolling interests (4,249) (4,930) (14,594) (16,173)
Benefit from income taxes 0 0 (962) (798)
Net loss (4,249) (4,930) (13,632) (15,375)
Less - net income (loss) attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (4,249) $ (4,930) $ (13,632) $ (15,375)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.49) $ (0.59) $ (1.58) $ (1.85)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.49) $ (0.59) $ (1.58) $ (1.85)
Weighted average common shares outstanding        
Basic shares (in shares) 8,738 8,321 8,649 8,307
Diluted shares (in shares) 8,738 8,321 8,649 8,307